This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi
by Zacks Equity Research
Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi are part of the Zacks top Analyst Blog.
SNYNegative Net Change BMYNegative Net Change MRKNegative Net Change GILDNegative Net Change ABBVNegative Net Change
pharmaceuticals
Buy, Sell or Hold ABBV Stock? Key Tips Ahead of Q1 Earnings
by Sundeep Ganoria
Investors will likely focus on the sales performance of AbbVie's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q1 results later this week.
RHHBYNegative Net Change JNJNegative Net Change ABBVNegative Net Change
biotechs earnings-preview medical pharmaceuticals
Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know
by Zacks Equity Research
INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
NVSNegative Net Change INCYNegative Net Change CTMXNegative Net Change ARGXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy?
by Kinjel Shah
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.
PFENegative Net Change NVOPositive Net Change LLYNegative Net Change BNTXNegative Net Change
pharmaceuticals
Regeneron to Report Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports first-quarter results on April 29.
REGNNegative Net Change AZNPositive Net Change GILDNegative Net Change VRTXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
by Ahan Chakraborty
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
SNYNegative Net Change BMYNegative Net Change MRKNegative Net Change GILDNegative Net Change ABBVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Merck Q1 Earnings Coming Up: Should You Buy the Stock Now?
by Kinjel Shah
When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.
AZNPositive Net Change MRKNegative Net Change SMMTNegative Net Change
pharmaceuticals
Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum?
by Zacks Equity Research
NVS' first-quarter performance has likely benefited from strong growth in Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix and Fabhalta.
AZNPositive Net Change NVSNegative Net Change GILDNegative Net Change VRTXNegative Net Change
biotechnology medical pharmaceuticals
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
by Zacks Equity Research
The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.
REGNNegative Net Change SNYNegative Net Change JAZZNegative Net Change KRYSNegative Net Change
pharmaceuticals
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
by Zacks Equity Research
Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?
by Zacks Equity Research
AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, are expected to have driven the company's top line.
SNYNegative Net Change AZNPositive Net Change AMGNNegative Net Change TEVANegative Net Change
pharmaceuticals
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
by Sundeep Ganoria
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
JAZZNegative Net Change HRMYNegative Net Change
biotechs cannabis marijuana marijuana-stocks medical pharmaceuticals
Bull of the Day: Hims & Hers Health (HIMS)
by Kevin Cook
Despite hiccups in GLP-1 market, HIMS estimates jump to +58% sales and +167% profits
HIMSPositive Net Change
medical pharmaceuticals smart-health
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?
by Ekta Bagri
Bristol Myers is looking to turn its business around, banking on the strong uptake of new drugs. However, the 2025 outlook is not bright and we recommend investors to wait and watch for now.
BMYNegative Net Change PFENegative Net Change TSVTNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?
by Ekta Bagri
Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now.
GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
by Sundeep Ganoria
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change CVACNegative Net Change
biotechs medical pharmaceuticals vaccines
GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59
by Zacks Equity Research
The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high risk of severe RSV disease.
GSKNegative Net Change PFENegative Net Change MRNANegative Net Change
biotechs pharmaceuticals
GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP
by Zacks Equity Research
The U.S. CDC's Advisory Committee recommends the use of GSK's pentavalent Penmenvy vaccine as part of the adolescent meningococcal vaccination schedule.
GSKNegative Net Change DVAXNegative Net Change BAYRYPositive Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback
by Kinjel Shah
JNJ beats first-quarter estimates for earnings and sales. PFE ends the development of the weight loss pill danuglipron.
SNYNegative Net Change RHHBYNegative Net Change JNJNegative Net Change PFENegative Net Change
pharmaceuticals
Here's How You Should Play JNJ Stock After Q1 Earnings Beat
by Kinjel Shah
Those who own JNJ stock may stay invested for some time to see how the company achieves growth in 2025 amid the various challenges.
JNJNegative Net Change AMGNNegative Net Change TEVANegative Net Change KVUEPositive Net Change
pharmaceuticals
Buy These Defensive Stocks After Beating Earnings Expectations?: ACI, JNJ
by Shaun Pruitt
Johnson & Johnson (JNJ) and Albertsons Companies' (ACI) stock have provided a pleasant hedge against market volatility and were able to exceed their quarterly expectations on Wednesday.
JNJNegative Net Change ACIPositive Net Change KRPositive Net Change
consumer-staples earnings investing large-cap medical pharmaceuticals
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News
by Ekta Bagri
BMY and VERV are in the spotlight this week following the failure of a late-stage study and positive cholesterol study data, respectively.
BIIBNegative Net Change IRWDPositive Net Change BMYNegative Net Change VERVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?
by Ekta Bagri
At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.
BMYNegative Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs cancer cell-therapy medical pharmaceuticals
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
by Zacks Equity Research
SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on lunsekimig and itepekimab studies.
REGNNegative Net Change SNYNegative Net Change JAZZNegative Net Change KRYSNegative Net Change
pharmaceuticals
Retail Sales, Q1 Earnings Show Signs of "Pull Forward"
by Mark Vickery
A trade tariff casualty - NVIDIA - is sending the Nasdaq lower than the other major indexes ahead of the open.
ABTNegative Net Change AMDPositive Net Change ALVPositive Net Change USBNegative Net Change TRVNegative Net Change NVDANegative Net Change AVGOPositive Net Change
auto-tires-trucks banking earnings finance inflation insurance pharmaceuticals